How Does It Compare to Other Tests?

The only assay designed for critical treatment decisions in clinically low- and intermediate-risk prostate cancer patients. See how the Oncotype DX GPS test compares to other genomic tests:

Comparison of prostate biopsy genomic tests

  Oncotype DX GPS assay Prolaris® Test Decipher® Prostate Biopsy Test
Genes selected based on their performance in prostate cancer in the biopsy setting1-4 checkmark
Extensive clinical validation across large cohorts of GS 3+3 and 3+4 patients who are eligible for active surveillance1,4-20 checkmark
Optimized and analytically validated for small prostate biopsy tissue samples2,10,19 checkmark
5 ng of RNA		 200 ng of RNA 25-100 ng of RNA

Validated endpoints in a biopsy setting:

Oncotype DX GPS assay
Prolaris® Test
Decipher® Prostate Biopsy Test
  • Metastasis after RP13
  • PCM after RP13
  • AP (Gleason grade ≥ 4+3 and/or pT3+)13*
  • BCR7,13
    		•
  • Metastasis after RP20
  • PCM after conservative management (watchful waiting)15,16
  • BCR20
    		•
  • Metastasis after RP3
  • PCM after RP3
  • AP (Gleason ≥ 4+3 and pT3b+ only)17*
    		•
    RP = radical prostatectomy; BCR = biochemical recurrence; PCM = prostate cancer mortality
    *Prospective validation data for this clinical endpoint.21
    Download Comparison Chart (PDF)

    MORE TOPICS:

  • Clinical validation trials
  • Is your patient eligible
  • How to order a test
    • REFERENCES

    * Adverse Pathology is defined as high-grade and/or non-organ-confined disease.

    1. Klein et al. Eur Urol. 2014.
    2. Cuzick et al. Lancet Oncol. 2011.
    3. Nguyen et al. Eur Urol. 2017.
    4. Erho et al. PLoS ONE. 2013.
    5. Badani et al. Urol Pract. 2015.
    6. Bonham et al. USCAP. 2016.
    7. Cullen et al. Eur Urol. 2015.
    8. Dall’Era et al. Urol Pract. 2015.
    9. Eggener et al. Urology. 2019.
    10. Knezevic et al. BMC Genomics. 2013.
    11. Lynch et al. Am J Manag Care. 2018.
    12. Salmasi et al. J Urol. 2018.
    13. Van Den Eeden et al. Eur Urol. 2017.
    14. Eure et al. Urology. 2017.
    15. Cuzick et al. Br J Cancer. 2015.
    16. Cuzick et al. Br J Cancer. 2012.
    17. Kim et al. Prostate Cancer Prostatic Dis. 2018.
    18. Albala et al. Rev Urol. 2016.
    19. Klein et al. Urol. 2016.
    20. Bishoff et al. J Urol. 2014.

    Stay in Touch

    Have questions? We're here to help.

     Contact Us
    Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
    In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
    Making cancer care smarter.®
    X

    We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.